CHRNA5 and CHRNA3 are promising candidate genes in the region of 15q25.1 for lung cancer.

Increased levels of cholinergic receptor nicotinic alpha 5 is associated with squamous cell lung carcinoma

The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer.(

the association between the alpha5 subunit nicotinic acetylcholine receptor single nucleotide polymorphism and lung cancer may, in part, be confounded by chronic obstructive pulmonary disease

smokers who carry the CHRNA3 and CHRNA5 variants are expected to be at increased risk for lung cancer compared with smokers who do not carry these alleles.

D398N polymorphism of the CHRNA5 gene was associated with lung adenocarcinoma.

Two distinct mechanisms conferring risk for nicotine dependence and lung cancer: altered receptor function caused by a D398N amino acid variant in CHRNA5 and variability in CHRNA5 mRNA expression.

Although CHRNA5 polymorphism is rare from Japanese lung cancer, polymorphism status might be correlated with shorter survival.

Single Nucleotide Polymorphism in CHRNA5 is associated with non-small cell lung cancer.

Smoking behavior and COPD are mediators of the association between the single nucleotide polymorphism (SNP) rs1051730 and the risk of lung cancer.

This review focuses on the clustered nicotinic acetylcholine receptor genes CHRNalpha5/alpha3/beta4 and evaluates their role in nicotine addiction and lung cancer.

A variation in the alpha5 subunit of nicotinic acetylcholine receptors increases the risk of nicotine dependence and lung cancer.

Results indicate that the CHRNA5 gene with under-activated or over-activated promoter activity may be protective against lung cancer, implying a complex role of the CHRNA5 gene in lung cancer.

CHRNA3-CHRNA5 variation impacts indirectly on lung cancer risk

Nicotinic acetylcholine receptor polymorphisms are associated with additional increased risk of lung cancer, bladder cancer, and chronic obstructive pulmonary disease after adjustment for smoking.

Variation in CHRNA5-A3-B4 was independently and additively associated with increased smoking, nicotine dependence, and lung cancer risk.

The A allele of the single nucleotide polymorphism rs16969968 (alpha5, G > A), which correlates with the development of lung cancer, shows a non-significant trend to be associated with cervical lesions.

results showed that several of the polymorphisms and their haplotypes in CHRNA5/CHRNA3 genes may have functional effects on (i) CHRNA5 mRNA levels, (ii) polycyclic aromatic hydrocarbon-DNA adduct levels, (iii) susceptibility to lung cancer

Single-nucleotide polymorphism in the CHRNA5 gene is associated with lung cancer susceptibility.

the heterozygous genotype c.-166T>A at rs503464 of CHRNA5 may be associated with reduced risk of lung cancer, thus representing a susceptibility allele in Chinese individuals.

Evaluated the association between CHRNA5-A3-B4 gene cluster variants (rs667282 and rs3743073, two variants modifying lung cancer risk) and risk of gastric cancer.

Nicotinic acetylcholine receptor subunits alpha4 and alpha5 associated with smoking behavior and lung cancer are regulated by upstream open reading frames.

Single nucleotide polymorphism in CHRNA5 is associated with lung cancer.

Our meta-analysis provided statistical evidence for a strong association between rs16969968 polymorphism and the risk of lung cancer, especially in smokers and Caucasians.

two SNPs (rs6495308 and rs11072768) in CHRNA5-A3-B4 have a indirect effect on lung cancer through smoking behaviors

rs2036527 is a risk factor for smoking exposure and lung cancer association in African-Americans.

Our present study suggested that rs667282 in CHRNA5-A3 may modify the prognosis of patients with advanced non-small cell lung cancer

quitting smoking is highly beneficial in reducing lung cancer risks for smokers regardless of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes, on average, can largely eliminate their elevated genetic risk for lung cancer by quitting smoking- cutting their risk of lung cancer in half and delaying its onset by 7years for those who develop it.

Frequency of the cholinergic receptor nicotinic alpha 5 (CHRNA5) rs16969968-A allele and cholinergic receptor nicotinic alpha 3 (CHRNA3) rs1051730-T allele were significantly higher in lung cancer than in normal controls.

CHRNA3/5 polymorphisms are associated with nicotine dependence, lung cancer, and chronic obstructive pulmonary disease in Mexicans.

CHRNA5 rs16969968 polymorphism is associated with lung cancer risk: A meta-analysis.

Low-Dose Nicotine Activates EGFR Signaling via alpha5-nAChR and Promotes lung Adenocarcinoma Progression.

The relationship between CHRNA5/A3/B4 gene cluster polymorphisms and lung cancer risk: An updated meta-analysis and systematic review.